WO1998022493A2 - DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES - Google Patents

DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES Download PDF

Info

Publication number
WO1998022493A2
WO1998022493A2 PCT/US1997/018704 US9718704W WO9822493A2 WO 1998022493 A2 WO1998022493 A2 WO 1998022493A2 US 9718704 W US9718704 W US 9718704W WO 9822493 A2 WO9822493 A2 WO 9822493A2
Authority
WO
WIPO (PCT)
Prior art keywords
dichlorophenyl
alanyl
group
methyl ester
alkyl
Prior art date
Application number
PCT/US1997/018704
Other languages
English (en)
Other versions
WO1998022493A3 (fr
Inventor
James E. Audia
Beverly K. Folmer
Varghese John
Lee H. Latimer
Jeffrey S. Nissen
Warren J. Porter
Eugene D. Thorsett
Jing Wu
Original Assignee
Elan Pharmaceuticals, Inc.
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals, Inc., Eli Lilly And Company filed Critical Elan Pharmaceuticals, Inc.
Priority to BR9714358A priority Critical patent/BR9714358A/pt
Priority to CA002270876A priority patent/CA2270876A1/fr
Priority to AU53543/98A priority patent/AU5354398A/en
Priority to NZ335157A priority patent/NZ335157A/xx
Priority to HU0001383A priority patent/HUP0001383A3/hu
Priority to IL12947797A priority patent/IL129477A0/xx
Priority to JP52364998A priority patent/JP2001519769A/ja
Priority to EP97950576A priority patent/EP0942923A2/fr
Publication of WO1998022493A2 publication Critical patent/WO1998022493A2/fr
Publication of WO1998022493A3 publication Critical patent/WO1998022493A3/fr
Priority to NO992426A priority patent/NO992426L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to compounds which inhibit 0-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease.
  • This invention also relates to pharmaceutical compositions comprising such compounds as well as methods for inhibiting release of ⁇ -amyloid peptide.
  • AD Alzheimer's Disease
  • AD failureia
  • AD in aged humans and is believed to represent the fourth most common medical cause of death in the United States.
  • AD has been observed in races and ethnic groups worldwide and presents a major present and future public health problem. The disease is currently estimated to affect about two to three million individuals in the United States alone. AD is at present incurable. No treatment that effectively prevents AD or reverses its symptoms and course is currently known.
  • the brains of individuals with AD exhibit characteristic lesions termed senile (or amyloid) plaques, amyloid angiopathy (amyloid deposits in blood vessels) and neurofibrillary tangles.
  • senile or amyloid
  • amyloid angiopathy amyloid deposits in blood vessels
  • neurofibrillary tangles Large numbers of these lesions, particularly amyloid plaques and neurofibrillary tangles, are generally found in several areas of the human brain important for memory and cognitive function in patients with AD. Smaller numbers of these lesions in a more restrictive anatomical distribution are also found in the brains of most aged humans who do not have clinical AD.
  • Amyloid plaques and amyloid angiopathy also characterize the brains of individuals with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type (HCHWA-D).
  • a definitive diagnosis of AD usually requires observing the aforementioned lesions in the brain tissue of patients who have died with the disease or, rarely, in small biopsied samples of brain tissue taken during an invasive neurosurgical procedure.
  • amyloid angiopathy amyloid angiopathy characteristic of AD and the other disorders mentioned above is an approximately 4.2 kilodalton (kD) protein of about 39-43 amino acids designated the /3-amyloid peptide ( / SAP) or sometimes A ⁇ , A3P or /3/A4.
  • ⁇ - Amyloid peptide was first purified and a partial amino acid sequence was provided by Glenner, et al. 1 The isolation procedure and the sequence data for the first 28 amino acids are described in U.S. Patent No. 4,666,829 2 .
  • / 3-amyloid peptide is a small fragment of a much larger precursor protein (APP), that is normally produced by cells in many tissues of various animals, including humans.
  • APP precursor protein
  • Knowledge of the structure of the gene encoding the APP has demonstrated that /3-amyloid peptide arises as a peptide fragment that is cleaved from APP by protease enzyme(s).
  • protease enzyme(s) The precise biochemical mechanism by which the / 3-amyloid peptide fragment is cleaved from APP and subsequently deposited as amyloid plaques in the cerebral tissue and in the walls of the cerebral and meningeal blood vessels is currently unknown.
  • a mutation at amino acid 693 of the 770-amino acid isoform of APP has been identified as the cause of the /3-amyloid peptide deposition disease, HCHWA-D, and a change from alanine to glycine at amino acid 692 appears to cause a phenotype that resembles AD is some patients but HCHWA-D in others.
  • the discovery of these and other mutations in APP in genetically based cases of AD prove that alteration of APP and subsequent deposition of its J-amyloid peptide fragment can cause AD.
  • the treatment methods would advantageously be based on drugs which are capable of inhibiting /3-amyloid peptide release and/or its synthesis.
  • This invention is directed to the discovery of a class of compounds which inhibit 3-amyloid peptide release and/or its synthesis and, therefore, are useful in the prevention of AD in patients susceptible to AD and/or in the treatment of patients with AD in order to inhibit further deterioration in their condition.
  • the class of compounds having the described properties are defined by formula I below:
  • R 1 is selected from the group consisting of (a) phenyl, (b) a substituted phenyl group of formula II:
  • R c is selected from the group consisting of acyl, alkyl, alkoxy, alkylalkoxy, azido, cyano, halo, hydrogen, nitro, trihalomethyl, thioalkoxy, and wherein R b and R c are fused to form a heteroaryl or heterocyclic ring with the phenyl ring,
  • R b and R b' are independently selected from the group consisting of hydrogen, halo, nitro, cyano, trihalomethyl, alkoxy, and thioalkoxy with the proviso that when R c is hydrogen, then R b and R b' are either both hydrogen or both substituents other than hydrogen,
  • substituted heteroaryl containing 1 to 3 substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, cyano, halo, nitro, heteroaryl, thioalkoxy and thioaryloxy provided that said substituents are not ortho (adjacent) to the heteroaryl attachment to the -NH group;
  • R 2 is selected from the group consisting of hydrogen, alkyl of from 1 to 4 carbon atoms, alkylalkoxy of from 1 to 4 carbon atoms, alkylthioalkoxy of from 1 to 4 carbon atoms, aryl, heteroaryl, substituted aryl and substituted heteroaryl provided that the substituents are not ortho (adjacent) to the attachment of the aryl or heteroaryl atom to the carbon atom;
  • R 3 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, substituted alkyl, substituted alkenyl, substituted alkynyl, and heterocyclic;
  • X is -C(O)Y where Y is selected from the group consisting of (a) alkyl,
  • substituted alkyl with the proviso that the substitution on said substituted alkyl does not include ⁇ -haloalkyl, ⁇ -diazoalkyl or ⁇ -OC(O)alkyl groups,
  • X can also be -CR 4 R 4 Y' where each R 4 is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic and Y' is selected from the group consisting of hydroxyl, amino, thiol, -OC(O)R 5 , -SSR 5 , -
  • this invention is directed to a method for inhibiting /3-amyloid peptide release and/or its synthesis in a cell which method comprises administering to such a cell an amount of a compound or a mixture of compounds of formula I above effective in inhibiting the cellular release and/or synthesis of /3-amyloid peptide.
  • this invention is directed to a prophylactic method for preventing the onset of AD in a patient at risk for developing AD which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically inert carrier and an effective amount of a compound or a mixture of compounds of formula I above.
  • this invention is directed to a therapeutic method for treating a patient with AD in order to inhibit further deterioration in the condition of that patient which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically inert carrier and an effective amount of a compound or a mixture of compounds of formula I above.
  • R 1 substituted phenyls are preferably 4-substituted, 3,5-disubstituted or 3,4-disubstituted phenyl substituents wherein the substituents at the 3 and/or 5 positions are defined by R b , R b' as above and the substituents at the 4 position is defined by R c as above.
  • Particularly preferred are 4-substituted, 3,5-disubstituted or 3,4-disubstituted phenyl substituents wherein the substituents at the 3 and/or 5 positions are defined by R b , R b' as above and the substituents at the 4 position is defined by R c as above.
  • 3,5-disubstituted phenyls include, by way of example, 3,5-dichlorophenyl, 3,5- difluorophenyl, 3,5-di(trifluoromethyl)phenyl, 3,5-dimethoxyphenyl, and the like.
  • preferred 3,4-disubstituted phenyls include, by way of example, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-(trifluoromethyl)-4- chlorophenyl, 3-chloro-4-cyanophenyl, 3-chloro-4-iodophenyl, 3,4- methylenedioxyphenyl, and the like.
  • Particularly preferred 4-substituted phenyls include, by way of example, 4-azidophenyl, 4-bromophenyl, 4- chlorophenyl, 4-cyanophenyl, 4-ethylphenyl, 4-fluorophenyl, 4-iodophenyl, 4- (phenylcarbonyl)phenyl, 4-(l-ethoxy)ethylphenyl, and the like.
  • R 1 substituents include, by way of example, 2-naphthyl, quinolin-3-yl, 2-methylquinolin-6-yl, benzothiazol-6-yl, benzothiazol-2-yl, 5-indolyl, phenyl, 2-naphthyl, and the like.
  • R 2 is selected from the group consisting of alkyl of from 1 to 4 carbon atoms, alkylalkoxy of from 1 to 4 carbon atoms, alkylthioalkoxy of from 1 to 4 carbon atoms, aryl, heteroaryl, substituted aryl and substituted heteroaryl provided that the substituents are not ortho to the attachment of the aryl or heteroaryl atom to the carbon atom.
  • Particularly preferred R 2 substituents include, by way of example, methyl, ethyl, /z-propyl, w ⁇ -propyl, n- butyl, iro-butyl, -CH 2 CH 2 SCH 3 , phenyl and the like.
  • R 3 substituents include alkyl groups such as methyl, ethyl, n-propyl, WO-propyl, n-butyl, wo-butyl, sec-butyl, and the like; substituted alkyl groups such as ⁇ -hydroxyefhyl, -CH 2 -cyclohexyl, benzyl, /j-hydroxybenzyl, 3-iodo-4-hydroxybenzyl, 3,5-diiodo-4-hydroxybenzyl, -CH 2 -indol-3-yl, phenyl,
  • Preferred X substituents include -C(O)Y groups where Y is methoxy, ethyoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t -butoxy, amino (-NH 2 ), N-(/ ⁇ ?-butyl)amino, N-methylamino, N,N-dimethylamino, N-benzylamino, and the like as well as where X is -CH 2 OH and the like.
  • This invention also provides for novel pharmaceutical compositions comprising a pharmaceutically inert carrier and a compound of the formula I above.
  • Particularly preferred compounds for use in the methods and compositions of this invention include, by way of example, the following wherein the stereochemistry of the R 2 and R 3 groups is preferably derived from the L-amino acid:
  • R 1 is selected from the group consisting of
  • R c is selected from the group consisting of acyl, alkyl, alkoxy, alkylalkoxy, azido, cyano, halo, hydrogen, nitro, trihalomethyl, thioalkoxy, and wherein R b and R c are fused to form a heteroaryl or heterocyclic ring with the phenyl ring,
  • R b and R b' are independently selected from the group consisting of hydrogen, halo, nitro, cyano, trihalomethyl, alkoxy, and thioalkoxy with the proviso that when R c is hydrogen, then R b and R b' are either both hydrogen or both substituents other than hydrogen, (c) 2-naphthyl, (d) 2-naphthyl substituted at the 4, 5, 6, 7 and/or 8 positions with 1 to 5 substituents selected from the group consisting of alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, thioalkoxy, aryl, and heteroaryl,
  • heteroaryl and (f) substituted heteroaryl containing 1 to 3 substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, cyano, halo, nitro, heteroaryl, thioalkoxy and thioaryloxy provided that said substituents are not ortho to the heteroaryl attachment to the -NH group;
  • R 2 is selected from the group consisting of hydrogen, alkyl of from 1 to 4 carbon atoms, alkylalkoxy of from 1 to 4 carbon atoms, alkylthioalkoxy of from 1 to 4 carbon atoms, aryl, heteroaryl, substituted aryl and substituted heteroaryl provided that the substituents are not ortho to the attachment of the aryl or heteroaryl atom to the carbon atom;
  • R 3 is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, substituted alkyl, substituted alkenyl, substituted alkynyl, and heterocyclic;
  • X is -C(O)Y where Y is selected from the group consisting of
  • R' and R" are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic, and where R' and R" are joined to form a cyclic group having from 2 to 8 carbon atoms optionally containing 1 to 2 additional heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen and optionally substituted with one or more alkyl or alkoxy groups, and when R 3 contains at least 3 carbon atoms, X can also be -CR 4 R 4 Y' where each R 4 is independendy selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic and Y' is selected from the group consisting of hydroxyl, amino, thiol, -OC(O)R 5 , -SSR 5 , -SSC(O)R 5 where R 5 is selected from the group consisting of alkyl, substituted
  • Preferred compounds of formula III above include those set forth below in Table I below:
  • this invention relates to compounds which inhibit / 3-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease.
  • this invention relates to compounds which inhibit / 3-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease.
  • /3-amyloid peptide refers to a 39-43 amino acid peptide having a molecular weight of about 4.2 kD which peptide is substantially homologous to the form of the protein described by Glenner, et al. 1 including mutations and post-translational modifications of the normal /3-amyloid peptide.
  • the ⁇ -amyloid peptide is approximately a 39-43 amino acid fragment of a large membrane-spanning glycoprotein, referred to as the ⁇ - amyloid precursor protein (APP). Its 43-amino acid sequence is: 1
  • Alkyl refers to monovalent alkyl groups preferably having from 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-p ⁇ opyl, n-butyl, iso- butyl, n-hexyl, and the like.
  • Substituted alkyl refers to an alkyl group, preferably of from 1 to 10 carbon atoms, having from 1 to 3 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, cycloalkyl, oxyacylamino, thiol, thioalkoxy, substituted thioalkoxy, aryl, heteroaryl, heterocyclic, nitro, and mono- and di-alkylamino, mono- and di- (substituted alkyl)amino, mono- and di-cycloalkylamino, mono- and di- arylamino, mono- and di-heteroaryl-amino, mono- and di-heterocyclic amino, and unsymmetric di-substituted amines having different substituents
  • Alkylene refers to divalent alkylene groups preferably having from 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), the propylene isomers (e.g. , -CH 2 CH 2 CH 2 - and -CH(CH 3 )CH 2 -) and the like.
  • Alkaryl refers to -alkylene-aryl groups preferably having from 1 to 10 carbon atoms in the alkylene moiety and from 6 to 10 carbon atoms in the aryl moiety. Such alkaryl groups are exemplified by benzyl, phenethyl and the like.
  • Alkoxy refers to the group “alkyl-O-”. Preferred alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, 77-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.
  • Substituted alkoxy refers to the group “substituted alkyl-O-" where substituted alkyl is as defined above.
  • Alkylalkoxy refers to the group “-alkylene-O-alkyl” where alkylene and alkyl are as defined above.
  • groups include, by way of example, methylenemethoxy (-CH 2 OCH 3 ), ethylenemethoxy (-CH 2 CH 2 OCH 3 ), n-propylene- ⁇ O-propoxy (-CH 2 CH 2 CH 2 OCH(CH 3 ) 2 ) , methylene-tert-butoxy (-CH 2 -O-C(CH 3 ) 3 ) and the like.
  • Alkylthioalkoxy refers to the group “-alkylene-S-alkyl” where alkylene and alkyl are as defined above.
  • groups include, by way of example, methylenethio ethoxy (-CH 2 SCH 3 ), ethylenethiomethoxy (-CH 2 CH 2 SCH 3 ), n-propylene-wo-thiopropoxy (-CH 2 CH 2 CH 2 SCH(CH 3 ) 2 ), methylenethio-t - butoxy (-CH 2 SC(CH 3 ) 3 ) and the like.
  • alkenyl refers to alkenyl groups preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkenyl unsaturation.
  • Substituted alkenyl refers to an alkenyl group as defined above having from 1 to 3 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, cyano, cycloalkyl, oxy acylamino, halogen, hydroxyl, carboxyl, carboxylalkyl, thiol, thioalkoxy, substituted thioalkoxy, aryl, heteroaryl, heterocyclic, nitro, and mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-cycloalkyl, mono- and di-arylamino, mono- and di-heteroarylamino, mono- and di-heterocyclic amino, and unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl,
  • Alkynyl refers to alkynyl groups preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkynyl unsaturation.
  • Preferred alkynyl groups include ethynyl (-C ⁇ CH), propargyl (-CH 2 C ⁇ CH) and the like.
  • Substituted alkynyl refers to an alkynyl group as defined above having from 1 to 3 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, cyano, cycloalkyl, oxyacylamino, halogen, hydroxyl, carboxyl, carboxylalkyl, thiol, thioalkoxy, substituted thioalkoxy, aryl, heteroaryl, heterocyclic, nitro, and mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-cycloalkylamino, mono- and di-arylamino, mono- and di- heteroarylamino, mono- and di-heterocyclic amino, and unsymmetric di- substituted amines having different substituents selected from alkyl, substituted alkyl, cyclo
  • Acyl refers to the groups alkyl-C(O)-, substituted alkyl-C(O)-, cycloalkyl-C(O)-, aryl-C(O)-, heteroaryl-C(O)- and heterocyclic-C(O)- where alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • Acylamino refers to the group -C(O)NRR where each R is independently hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclic and where each of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • Aminoacyl refers to the group -NRC(O)R where each R is independently hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclic and where each of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • Alkyloxy refers to the groups -OC(O)-alkyl, -OC(O)-substituted alkyl, -OC(O)-cycloalkyl, -OC(O)-aryl, -C(O)O-heteroaryl-, and -C(O)O-heterocyclic where alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • Aminoacyloxy refers to the groups -NRC(O)O-alkyl, -NRC(O)O- substituted alkyl, -NRC(O)O-cycloalkyl, -NRC(O)O-aryl, -NRC(O)O- heteroaryl-, and -NRC(O)O-heterocyclic where R is hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclic and where each of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • Oxyacylamino refers to the groups -OC(O)NR-alkyl, -OC(O)NR- substituted alkyl, -OC(O)NR-aryl, -OC(O)NR-heteroaryl-, and -OC(O)NR- heterocyclic where R is hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclic and where each of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
  • Aryl refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g. , naphthyl or anthryl). Preferred aryls include phenyl, naphthyl and the like.
  • such aryl groups can optionally be substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino, aminoacyl, acylamino, aminoacyloxy, oxyacylamino, aryl, aryloxy, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, trihalomethyl, thioalkoxy, substituted thioalkoxy, mono- and di- alkylamino, mono- and di-(substituted alkyl)amino, mono- and di- cycloalkylamino, mono- and di-arylamino, mono-and di-heteroarylamino, mono- and di-hetero
  • Preferred substituents include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy. When so substituted, such aryl groups are sometimes referred to herein as "substituted aryl".
  • Aryloxy refers to the group aryl-O- wherein the aryl group is as defined above including optionally substituted aryl groups as also defined above.
  • Carboxyalkyl refers to the groups -C(O)O-alkyl
  • alkyl and substituted alkyl are as defined herein.
  • Cycloalkyl refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings (including aromatic rings fused to the cycloalkyl ring) which can be optionally substituted with from 1 to 3 alkyl groups.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, 1- methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like, or multiple ring structures such as dibenzosuberane, adamantanyl, and the like.
  • Cycloalkenyl refers to cyclic alkenyl groups of from 4 to 8 carbon atoms having a single cyclic ring or multiple condensed rings and at least one point of internal unsaturation which can be optionally substituted with from 1 to 3 alkyl groups.
  • suitable cycloalkenyl groups include, for instance, cyclobut-2-enyl, cyclopent-3-enyl, cyclooct-3-enyl and the like.
  • Halo or halogen refers to fluoro, chloro, bromo and iodo and preferably is either chloro or bromo.
  • Heteroaryl refers to a monovalent aromatic group of from 2 to 10 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within the ring.
  • heteroaryl groups can be optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino, aminoacyl, acylamino, aminoacyloxy, oxyacylamino, aryl, aryloxy, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, trihalomethyl, thioalkoxy, substituted thioalkoxy, mono- and di- alkylamino, mono- and di-(substituted alkyl)amino, mono- and di- cycloalkylamino, mono- and di-arylamino, mono-and di-heteroarylamino, mono- and di-heterocycl
  • heteroaryl groups can have a single ring (e.g., pyridyl, furyl, etc.) or multiple condensed rings (e.g., indolizinyl or benzothienyl).
  • Preferred heteroaryls include pyridyl, pyrrolyl, and furyl. When so substituted, such heteroaryl groups are sometimes referred to herein as "substituted heteroaryl".
  • Heterocycle or “heterocyclic” refers to a monovalent saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 12 carbon atoms and from 1 to 4 hetero atoms selected from nitrogen, sulfur or oxygen within the ring.
  • heterocyclic groups can be optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, acyl, acyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amino, aminoacyl, acylamino, aminoacyloxy, oxyacylamino, aryl, aryloxy, carboxyl, carboxylalkyl, cyano, halo, nitro, heteroaryl, trihalomethyl, thioalkoxy, substituted thioalkoxy, mono- and di- alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono-and di-heteroarylamino, mono- and di-heterocyclic amino, and unsymmetric di-substituted
  • heterocycles and heteroaryls include, but are not limited to, furan, thiophene, thiazole, oxazole, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide,
  • Thiol refers to the group -SH.
  • Thioalkoxy refers to the group -S-alkyl.
  • Substituted thioalkoxy refers to the group -S-substituted alkyl.
  • Thioaryloxy refers to the group aryl-S- wherein the aryl group is as defined above including optionally substituted aryl groups as also defined above.
  • Thioheteroaryloxy refers to the group heteroaryl-S- wherein the heteroaryl group is as defined above including optionally substituted aryl groups as also defined above.
  • R b and R c can be fused to form a heteroaryl or heterocyclic ring with the phenyl ring. Fusion in this manner results in a fused bicyclic ring structure of the formula:
  • R b' is as defined above and A is the fused heteroaryl or heterocyclic group as these terms are as defined above wherein the two atoms of the phenyl ring are included in the total atoms present in the heteroaryl or heterocyclic group.
  • fused ring systems include, for instance, indol-5-yl, indol-6-yl, thionaphthen-5-yl, thionaphthen-6-yl, isothionaphthen-5-yl, isothionaphthen-6-yl, indoxazin-5-yl, indoxazin-6-yl, benzoxazol-5-yl, benzoxazol-6-yl, anthranil-5-yl, anthranil-6-yl, quinolin-6-yl, quinolin-7-yl, isoquinolin-6-yl, isoquinolin-7-yl, cinnolin-6-yl, cinnolin-7-yl, quinazolin-6-yl, quinazolin-7-yl, benzofuran-5-yl, benzofuran-6-yl, isobenzofuran-5-yl, isobenzofuran-6-yl,
  • “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts of a compound of Formula I which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • the R 1 group of the amino acid NH 2 CH(R )COOH or an ester thereof is first introduced onto the molecule. Afterwards, conventional coupling of the first R 1 NHCH(R 2 )COOH or ester thereof with the amine of NH 2 CH(R 3 )C(O)Y provides for compounds of formula I wherein X is -C(O)Y.
  • R 1 and R 2 are as defined above and X' is preferably a halo group such as chloro or bromo.
  • leaving groups other than halo may be employed such as triflate, mesylate, tosylate and the like.
  • suitable esters of 1 may be employed in this reaction.
  • Reaction (1) involves coupling of a suitable haloacetic acid derivative 1 with a primary aryl/heteroarylamine 2 under conditions which provide for amino acid 3.
  • This reaction is described by, for example, Yates, et al. 10 and proceeds by combining approximately stoichiometric equivalents of haloacetic acid 1 with primary aryl/heteroarylamine 2 in a suitable inert diluent such as water, dimethylsulfoxide (DMSO) and the like.
  • DMSO dimethylsulfoxide
  • the reaction employs an excess of a suitable base such as sodium bicarbonate, sodium hydroxide, etc. to scavenge the acid generated by the reaction.
  • reaction (1) is preferably conducted at from about 25 °C to about 100°C until reaction completion which typically occurs within 1 to about 24 hours. This reaction is further described in U.S. Patent No. 3,598,859, which is incorporated herein by reference in its entirety.
  • N-aryl/N-heteroaryl amino acid 3 is recovered by conventional methods including precipitation, chromatography, filtration and the like.
  • each of the reagents haloacetic acid 1, primary aryl/heteroarylamine 2 and alcohol 3
  • the R 1 group can be coupled to an alanine ester (or other suitable amino acid ester) by conventional N-arylation.
  • a stoichiometric equivalent or slight excess of the amino acid ester can be dissolved in a suitable diluent such as DMSO and coupled with a haloaryl compound, X-R 1 where X is a halo group such as fluoro, chloro or bromo and R 1 is as defined above.
  • the reaction is conducted in the presence of an excess of base such as sodium hydroxide to scavenge the acid generated by the reaction.
  • the reaction typically proceeds at from 15 °C to about 250°C and is complete in about 1 to 24 hours.
  • N-aryl amino acid ester is recovered by conventional methods including chromatography, filtration and the like.
  • esterified amino acids of formula I above can be prepared by reductive amination of a suitable 2- oxocarboxylic acid ester (such as a pyruvate ester) in the manner illustrated in Reaction (2) below:
  • R 1 and R 2 are as defined above.
  • reaction (2) approximately stoichiometric equivalents of a 2- oxocarboxylic acid ester 6 and arylamine 2 are combined in an inert diluent such as methanol, ethanol and the like and the reaction solution treated under conditions which provide for imine formation (not shown).
  • the imine formed is then reduced under conventional conditions by a suitable reducing agent such as sodium cyanoborohydride, H 2 /palladium on carbon and the like to form the N-aryl amino acid ester 5.
  • the reducing agent is H 2 /palladium on carbon which is incorporated into the initial reaction medium which permits imine reduction in situ in a one pot procedure to provide for the N-aryl amino acid ester 5.
  • reaction is preferably conducted at from about 20°C to about 80°C at a pressure of from 1 to 10 atmospheres until reaction completion which typically occurs within 1 to about 24 hours.
  • N-aryl amino acid ester 5 is recovered by conventional methods including chromatography, filtration and the like.
  • a further embodiment for preparing N-aryl amino acids includes aromatic nucleophilic substitution of fluorobenzenes by the amine group of an amino acid.
  • the carboxylic acid derivative 5 is then coupled under conventional conditions well known in the art with a compound of the formula NH 2 CH(R 3 )C(O)Y where R 3 and Y are as defined above. Such coupling leads to compounds of formula I. Subsequent modifications (e.g., reduction) lead to further compounds of formula I.
  • Y is an ester group
  • conventional transesterification techniques can be used to prepare a variety of different ester groups on the compounds of formula I.
  • Numerous techniques are known in the art to effect transesterification and each technique merely replaces the ester group with a different ester group derived from the corresponding alcohol or thioalcohol and, in some cases, a catalyst such as titanium (IV) w ⁇ -propoxide is used to facilitate reaction completion.
  • the alcohol or thioalcohol is first treated with sodium hydride in a suitable diluent such as toluene to form the corresponding sodium alkoxide or thioalkoxide which is then employed to effect transesterification.
  • a suitable diluent such as toluene
  • the efficiency of this technique makes it particularly useful with high boiling and/or expensive alcohols.
  • the ester to be transesterified is placed in a large excess of the alcohol or thioalcohol which effects transesterification.
  • a catalytic amount of sodium hydride is then added and the reaction proceeds quickly under conventional conditions to provide the desired transesterified product. Because this protocol requires the use of a large excess of alcohol or thioalcohol, this procedure is particularly useful when the alcohol is inexpensive.
  • Transesterification provides a facile means to provide for a multiplicity of different ester substituents on the compounds of formula I above.
  • the alcohols and thioalcohols employed to effect transesterification are well known in the art with a significant number being commercially available.
  • esters of this invention include, by way of example, first hydrolyzing the ester to the free acid followed by O-alkylation with, e.g. , a haloalkyl group in the presence of a base such as potassium carbonate.
  • reaction is conventionally conducted in an inert aprotic diluent such as dimethylformamide, dichloromethane, chloroform, acetonitrile, tetrahydrofuran and the like.
  • an inert aprotic diluent such as dimethylformamide, dichloromethane, chloroform, acetonitrile, tetrahydrofuran and the like.
  • ketones can be prepared by coupling the suitable aminoketone ⁇ Cl salt with the terminal carboxyl group of the amino acid.
  • the starting materials can contain a chiral center (e.g., alanine) and, when a racemic starting material is employed, the resulting product is a mixture of diastereomers or R,S enantiomers.
  • a chiral isomer of the starting material can be employed and, if the reaction protocol employed does not racemize this starting material, a chiral product is obtained.
  • Such reaction protocols can involve inversion of the chiral center during synthesis.
  • the products of this invention are a mixture of diastereomers (if two or more chiral centers are present) or
  • R,S enantiomers (if only one chiral center is present).
  • the chiral product corresponds to the L-amino acid derivative.
  • chiral products can be obtained via purification techniques which separates diastereomers or enantiomers from a R,S mixture to provide for one or the other stereoisomer. Such techniques are well known in the art.
  • the compounds of formula I are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
  • compositions which contain, as the active ingredient, one or more of the compounds of formula I above associated with pharmaceutically acceptable carriers.
  • the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
  • the active compound In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy- benzoates; sweetening agents; and flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the compound of formula I above is employed at no more than about 20 weight percent of the pharmaceutical composition, more preferably no more than about 15 weight percent, with the balance being pharmaceutically inert carrier(s).
  • the active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as corn oil, cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
  • the above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.
  • the components are blended and compressed to form tablets, each weighing 240 mg.
  • Formulation Example 3 A dry powder inhaler formulation is prepared containing the following components:
  • the active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly.
  • the solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve.
  • the granules so produced are dried at 50° to 60 °C and passed through a 16 mesh U.S. sieve.
  • the sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.
  • Suppositories each containing 25 mg of active ingredient are made as follows:
  • the active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.
  • the active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water.
  • the sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.
  • the active ingredient, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in
  • a subcutaneous formulation may be prepared as follows: Ingredient Quantity
  • a topical formulation may be prepared as follows:
  • the white soft paraffin is heated until molten.
  • the liquid paraffin and emulsifying wax are incorporated and stirred until dissolved.
  • the active ingredient is added and stirring is continued until dispersed.
  • the mixture is then cooled until solid.
  • transdermal delivery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g.. U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference.
  • patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • Indirect techniques usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophihc drugs into lipid-soluble drugs.
  • Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier.
  • the delivery of hydrophihc drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.
  • Other suitable formulations for use in the present invention can be found in Remington 's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985).
  • the compounds and pharmaceutical compositions of the invention are useful in inhibiting /3-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease in mammals including humans.
  • the compounds described herein are suitable for use in a variety of drug delivery systems described above. Additionally, in order to enhance the in vivo serum half-life of the administered compound, the compounds may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the compounds.
  • a variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., U.S. Patent Nos. 4,235,871, 4,501 ,728 and 4,837,028 each of which is incorporated herein by reference.
  • compositions are administered to a patient already suffering from AD in an amount sufficient to at least partially arrest further onset of the symptoms of the disease and its complications.
  • An amount adequate to accomplish this is defined as "therapeutically effective dose.
  • Amounts effective for this use will depend on the judgment of the attending clinician depending upon factors such as the degree or severity of AD in the patient, the age, weight and general condition of the patient, and the like.
  • the compounds described herein are administered at dosages ranging from about 0.1 to about 500 mg/kg/day.
  • compositions are administered to a patient at risk of developing AD (determined for example by genetic screening or familial trait) in an amount sufficient to inhibit the onset of symptoms of the disease.
  • An amount adequate to accomplish this is defined as "prophylactically effective dose. " Amounts effective for this use will depend on the judgment of the attending clinician depending upon factors such as the age, weight and general condition of the patient, and the like.
  • the compounds described herein are administered at dosages ranging from about 0.1 to about 500 mg/kg/day.
  • the compounds administered to a patient are in the form of pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. When aqueous solutions are employed, these may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the compound preparations typically will be between 3 and 11 , more preferably from 5 to 9 and most preferably from 7 and 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
  • EDC l-(3-dimethyaminopropyl)-ethylcarbodiimide hydrochloride
  • OD optical density
  • pg picograms
  • pM picomolar
  • psi pounds per square inch
  • rpm rotations per minute
  • rt room temperature
  • ⁇ g microgram
  • ⁇ L microliter
  • Aldrich indicates that the compound or reagent used in the following procedures is commercially available from Aldrich Chemical Company, Inc. , 1001 West Saint Paul Avenue, Milwaukee, WI 53233 USA; the term “Bachem” indicates the compound or reagent is commercially available from Bachem Biosciences Inc. , 3700 Horizon Drive, Renaissance at Gulph Mills, King of Prussia, PA 19406 USA; the term “Fluka” indicates the compound or reagent is commercially available from Fluka Chemical Corp., 980 South 2nd Street, Ronkonkoma, NY 11779 USA; the term “Lancaster” indicates the compound or reagent is commercially available from Lancaster
  • GENERAL PROCEDURE C Ester Hydrolysis to Free Acid Ester hydrolysis to the free acid was conducted by conventional methods. Below are two examples of such conventional de-esterification methods.
  • the amino acid ester was dissolved in dioxane/water (4: 1) to which was added LiOH ( - 2 eq.) that was dissolved in water such that the total solvent after addition was about 2: 1 dioxane: water.
  • the reaction mixture was stirred until reaction completion and the dioxane was removed under reduced pressure.
  • the residue was diluted with EtOAc, the layers were separated and the aqueous layer acidified to pH 2.
  • the aqueous layer was back extracted with EtOAc, the combined organics were dried over Na 2 SO 4 and the solvent was removed under reduced pressure after filtration.
  • the residue was purified by conventional methods (e.g. , recrystallization).
  • the carboxylic acid was dissolved in methylene chloride.
  • the amino acid ester/amide (1 eq.), N-mefhylmorpholine (5 eq.) and hydroxybenzotriazole monohydrate (1.2 eq.) were added in sequence.
  • a cooling bath was applied to the round bottomed flask until the solution reached 0°C.
  • 1.2 eq. of l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was added.
  • the solution was allowed to stir overnight and come to room temperature under nitrogen pressure.
  • the reaction mixture was worked up by washing the organic phase with saturated aqueous sodium carbonate, 0. IM citric acid, and brine before drying with sodium sulfate.
  • the solvents were then removed to yield crude product. Pure products were obtained by flash chromatography in an appropriate solvent.
  • the reaction was cooled to room temperature, then the pH was adjusted to ⁇ 4.
  • the precipitated mono-nosylated aminoquinoline was removed by filtration and washed with H 2 O.
  • a solution of this compound in THF was then added to a -78 °C suspension of NaH in THF, then ethyl 2- bromopropionate was added.
  • the reaction was warmed to it, then refluxed for 4 days.
  • the crude reaction mixture was stripped free of solvent on a rotary evaporator, and the alkylated, nosylated aminoquinoline was obtained by chromatography. This product was then dissolved in DMF and 3 equivalents K 2 CO 3 was added, followed by 1.2 equivalents of thiophenol. The reaction was stirred overnight at room temperature.
  • the reaction was then quenched with water and ether, and the organic phase was washed with saturated aqueous NaHCO 3 and saturated aqueous NaCl, then dried over MgSO 4 .
  • the solution was stripped free of solvent on a rotary evaporator to yield the crude product, which was then purified through chromatography.
  • reaction volume was reduced to — 1/3 of initial volume under reduced pressure.
  • aqueous potassium sodium tartrate 20% aqueous potassium sodium tartrate
  • amino acid (amino acid or amino acid hydrochloride) is suspended in methanol and chilled to 0°C. HCI gas is bubbled through this solution for 5 min. The reaction is allowed to warm to room temperature then stirred for 4 hours. The solvents are then removed to afford the desired amino acid methyl ester hydrochloride. This product is usually used without further purification.
  • N-(3,4-dichlorophenyl)-D,L-alanine was prepared. Specifically, to a solution of 3,4- dichloroaniline (1 equivalent) (Aldrich) in isopropanol (about 500 mL per mole of 3,4-dichloroaniline) is added water (about 0.06 mL per mL of isopropanol) and 2-chloropropionic acid (2 equivalents) (Aldrich).
  • Example B Synthesis of N-(3,5-dichlorophenyl)-D,L-alanine Using the procedure set forth in U.S. Patent No. 3,598,859 (or Example A above), N-(3,5-dichlorophenyl)-D,L-alanine was prepared using 3,5- dichloroaniline (Aldrich) and 2-chloropropionic acid (Aldrich).
  • N-(3,5-difluorophenyl)-D,L-alanine was prepared using 3,5- difluoroaniline (Aldrich) and 2-chloropropionic acid (Aldrich).
  • Example F Synthesis of BOC- ⁇ orleucine amide
  • BOC-norleucine BOC-norleucine (Bachem)
  • 3.44 g (22.5 mmol) of 1-hydroxybenzotriazole monohydrate and 50 mL of dichloromethane at 0°C 3.45 g (1.2 mmol) of EDC.
  • the resulting mixture was stirred at 0°C for 1 hour and then ammonia gas was bubbled through the mixture for 10 min.
  • the cooling bath was allowed to warm to room temperature and the mixture stirred for 18 hours.
  • the mixture was evaporated to dryness, triturated with 20% Na 2 CO 3 .
  • the resulting solid was collected by filtration and washed with water to yield 2.69 g (11.7 mmol, 78%) of the title compound.
  • Step B N-[3,5-Di(trifluoromethyl)phenyl]-L-alanine isobutyl ester was then hydrolyzed according to General Procedure C using lithium hydroxide in THF.
  • N-(3,4-dichlorophenyl)glycine was prepared using 3,4-dichloroaniline (Aldrich) and 2- chloroacetic acid (Aldrich).
  • reaction product was purified by silica gel chromatography using 50% ethyl acetate/hexane.
  • Step A Synthesis of N-[N-benzothiazoI-6-yl)-D,L-alanine
  • a solution of 1 gram of 6-aminobenzothiazole (Lancaster) in 60 mL of dichloromethane was treated with 0.63 grams of pyridine and then 2.1 grams of trifluoroacetic acid anhydride at room temperature. The reaction was stirred for 3 hours during which time the initially warm reaction mixture cooled to room temperature. The mixture was washed with a 5 % aqueous citric acid solution, dried with MgS0 4 and the solvents removed to provide a quantitative yield of 6-aminobenzotriazole trifluoroacetamide as a cream colored solid that was used immediately in the following reaction.
  • Step B Synthesis of N-[N-benzothiazol-6-yl)-D,L-alanyl]-(S)-2- aminohexanoic acid methyl ester
  • ⁇ -nmr (CD 3 OD) ⁇ 6.49 (m, IH), 6.32 (m, IH), 1.14 (m, IH), 3.54- 3.71 (m, IH), 0.80-1.62 (m, 9H), 0.68 (m, 1.5H), 0.58 (m, 1.5H).
  • Example 61 Cellular Screen for the Detection of Inhibitors of ⁇ -Amyloid Production
  • Numerous compounds of formula I above were assayed for their ability to inhibit / 3-amyloid production in a cell line possessing the Swedish mutation.
  • the media were again removed and replaced with fresh drug containing media as above and cells were incubated for an additional two hours.
  • plates were centrifuged in a Beckman GPR at 1200 rpm for five minutes at room temperature to pellet cellular debris from the conditioned media. From each well, 100 ⁇ L of conditioned media or appropriate dilutions thereof were transferred into an
  • ELISA plate precoated with antibody 266 [P. Seubert, Nature (1992) 359:325- 327] against amino acids 13-28 of /3-amyloid peptide as described in International Patent Application Publication No. 94/10569 8 and stored at 4°C overnight.
  • An ELISA assay employing labelled antibody 6C6 [P. Seubert, Nature (1992) 359:325-327] against amino acids 1-16 of /3-amyloid peptide was run the next day to measure the amount of /3-amyloid peptide produced.
  • Cytotoxic effects of the compounds were measured by a modification of the method of Hansen, et al. 12 .
  • To the cells remaining in the tissue culture plate was added 25 ⁇ L of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, MO) stock solution (5 mg/mL) to a final concentration of 1 mg/mL.
  • MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
  • results of the /3-amyloid peptide ELISA were fit to a standard curve and expressed as ng/mL /3-amyloid peptide. In order to normalize for cytotoxicity, these results were divided by the MTT results and expressed as a percentage of the results from a drug free control. All results are the mean and standard deviation of at least six replicate assays.
  • test compounds were assayed for /3-amyloid peptide production inhibition activity in cells using this assay.
  • the results of this assay demonstrate that, each of the compounds of Examples 1-60 inhibit the ⁇ - amyloid peptide production by at least 30% as compared to control.
  • This example illustrates how the compounds of this invention could be tested for in vivo suppression of /3-amyloid release and/or synthesis.
  • 3 to 4 month old PDAPP mice are used [Games et al. , (1995) Nature 373:523-527].
  • the compound is usually formulated at either 5 or 10 mg/mL. Because of the low solubility factors of the compounds, they may be formulated with various vehicles, such as corn oil (Safeway, South San Francisco, CA); 10% ethanol in corn oil; 2-hydroxypropyl-/3-cyclodextrin (Research Biochemicals International, Natick MA); and carboxymethylcellulose (Sigma Chemical Co., St. Louis MO).
  • mice are dosed subcutaneously with a 26 gauge needle and 3 hours later the animals are euthanized via CO 2 narcosis and blood is taken by cardiac puncture using a 1 cc 25G 5/8" tuberculin syringe/needle coated with solution of 0.5 M EDTA, pH 8.0.
  • the blood is placed in a Becton-Dickinson vacutainer tube containing EDTA and spun down for 15 minutes at 1500 x gravity at 5°C.
  • the brains of the mice are then removed and the cortex and hippocampus are dissected out and placed on ice.
  • each brain region is homogenized in 10 volumes of ice cold guanidine buffer (5.0 M guanidine-HCl, 50 mM Tris-HCl, pH 8.0) using a Kontes motorized pestle (Fisher, Pittsburgh PA). The homogenates are gently rocked on a rotating platform for three to four hours at room temperature and stored at -20 °C prior to quantitation of /3-amyloid.
  • the brain homogenates are diluted 1: 10 with ice-cold casein buffer [0.25% casein, phosphate buffered saline (PBS), 0.05% sodium azide, 20 ⁇ g/mL aprotinin, 5 mM EDTA, pH 8.0, 10 ⁇ g/mL leupeptin], thereby reducing the final concentration of guanidine to 0.5 M, before centrifugation at 16,000 x gravity for 20 minutes at 4°C.
  • PBS phosphate buffered saline
  • the /3-amyloid standards (1-40 or 1-42 amino acids) were prepared such that the final composition equaled 0.5 M guanidine in the presence of 0.1 % bovine serum albumin (BSA).
  • the total /3-amyloid sandwich ELISA, quantitating both /3-amyloid (aa 1- 40) and / 3-amyloid (aa 1-42) consists of two monoclonal antibodies (mAb) to ⁇ - amyloid.
  • the capture antibody, 266 [P. Seubert, Nature (1992) 359:325-327], is specific to amino acids 13 - 28 of 3-amyloid.
  • the antibody 3D6 [Johnson- Wood et al., PNAS USA (1997) 94: 1550-1555], which is specific to amino acids 1 - 5 of /3-amyloid, is biotinylated and served as the reporter antibody in the assay.
  • the 3D6 biotinylation procedure employs the manufacturer's (Pierce,
  • the assay has a lower limit of sensitivity of - 50 pg/mL (11 pM) and shows no cross- reactivity to the endogenous murine /3-amyloid peptide at concentrations up to 1 ng/mL.
  • the configuration of the sandwich ELISA quantitating the level of ⁇ - amyloid (aa 1-42) employs the mAb 2 IF 12 [Johnson-Wood et al., PNAS USA
  • Biotinylated 3D6 is also the reporter antibody in this assay which has a lower limit of sensitivity of - 125 pg/mL (28 pM).
  • the 266 and 21F12 capture mAbs are coated at 10 ⁇ g/mL into 96 well immunoassay plates (Costar, Cambidge MA) overnight at room temperature.
  • the plates are then aspirated and blocked with 0.25 % human serum albumin in PBS buffer for at least 1 hour at room temperature, then stored desiccated at 4°C until use.
  • the plates are rehydrated with wash buffer (Tris-buffered saline, 0.05% Tween 20) prior to use.
  • the samples and standards are added to the plates and incubated overnight at 4°C.
  • the plates are washed > 3 times with wash buffer between each step of the assay.
  • the biotinylated 3D6, diluted to 0.5 ⁇ g/mL in casein incubation buffer (0.25% casein, PBS, 0.05 % Tween 20, pH 7.4) is incubated in the well for 1 hour at room temperature.
  • Avidin- HRP Vector, Burlingame CA
  • diluted 1:4000 in casein incubation buffer is added to the wells for 1 hour at room temperature.
  • the colorimetric substrate
  • the EDTA plasma is diluted 1 : 1 in specimen diluent (0.2 g/L sodium phosphate H 2 O (monobasic), 2.16 g/L sodium phosphate* 7H 2 O (dibasic), 0.5 g/L thimerosal, 8.5 g/L sodium chloride, 0.5 mL Triton X-405, 6.0 g/L globulin-free bovine serum albumin; and water).
  • the samples and standards in specimen diluent are assayed using the total /3-amyloid assay (266 capture/3D6 reporter) described above for the brain assay except the specimen diluent was used instead of the casein diluents described.
  • Gly Ala lie lie Gly Leu Met Val Gly Gly Val Val lie Ala 30 35 40

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a trait à des composés inhibant la libération de peptide β-amyloïde et ou sa synthèse et, de ce fait, se révélant utiles s'agissant de traiter la maladie d'Alzheimer. Elle a également trait à des compositions pharmaceutiques contenant un composé inhibant la libération de peptide β-amyloïde et ou sa synthèse ainsi qu'à des méthodes de traitement de la maladie d'Alzheimer, tant au plan prophylactique que thérapeutique, ces méthodes faisant intervenir lesdites compositions pharmaceutiques.
PCT/US1997/018704 1996-11-22 1997-11-20 DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES WO1998022493A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR9714358A BR9714358A (pt) 1996-11-22 1997-11-20 Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
CA002270876A CA2270876A1 (fr) 1996-11-22 1997-11-20 Derives de n-(aryl/heteroaryl) aminoacide, compositions pharmaceutiques les contenant et procedes permettant d'inhiber la liberation de peptide .beta. amyloide et/ou sa synthese al'aide de ces composes
AU53543/98A AU5354398A (en) 1996-11-22 1997-11-20 N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions compri sing same, and methods for inhibiting beta-amyloid peptide release and/or it s synthesis by use of such compounds
NZ335157A NZ335157A (en) 1996-11-22 1997-11-20 N-(aryl/heteroaryl) amino acid derivatives and methods for inhibiting beta-amyloid peptide release or its synthesis
HU0001383A HUP0001383A3 (en) 1996-11-22 1997-11-20 N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use
IL12947797A IL129477A0 (en) 1996-11-22 1997-11-20 N-(aryl/heteroaryl)amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
JP52364998A JP2001519769A (ja) 1996-11-22 1997-11-20 Ｎ―（アリール／ヘテロアリール）アミノ酸誘導体、その医薬組成物および該化合物を用いたβ―アミロイドペプチドの放出および／またはその合成を阻害する方法
EP97950576A EP0942923A2 (fr) 1996-11-22 1997-11-20 DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE $g(b) AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES
NO992426A NO992426L (no) 1996-11-22 1999-05-20 N-(aryl/heteroaryl)aminosyrederivater, farmas°ytiske sammensetninger som omfatter det samme, og metoder for inhibering av <beta>-amyloidpeptid frigivelse og/eller dens syntese ved bruk av slike forbindelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75533496A 1996-11-22 1996-11-22
US08/755,334 1996-11-22

Publications (2)

Publication Number Publication Date
WO1998022493A2 true WO1998022493A2 (fr) 1998-05-28
WO1998022493A3 WO1998022493A3 (fr) 1998-07-23

Family

ID=25038718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018704 WO1998022493A2 (fr) 1996-11-22 1997-11-20 DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES

Country Status (13)

Country Link
EP (1) EP0942923A2 (fr)
JP (1) JP2001519769A (fr)
CN (1) CN1237978A (fr)
AU (1) AU5354398A (fr)
BR (1) BR9714358A (fr)
CA (1) CA2270876A1 (fr)
HU (1) HUP0001383A3 (fr)
ID (1) ID22275A (fr)
IL (1) IL129477A0 (fr)
NO (1) NO992426L (fr)
NZ (1) NZ335157A (fr)
TR (1) TR199901132T2 (fr)
WO (1) WO1998022493A2 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
US6486350B1 (en) 1998-09-30 2002-11-26 Elan Pharmaceuticals Inc. Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide
US6503901B1 (en) 1999-10-08 2003-01-07 Bristol Myers Squibb Pharma Company Amino lactam sulfonamides as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6509333B2 (en) 2000-06-01 2003-01-21 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of Aβ protein production
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
US6610734B2 (en) 2000-12-13 2003-08-26 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
US6713476B2 (en) 2000-04-03 2004-03-30 Dupont Pharmaceuticals Company Substituted cycloalkyls as inhibitors of a beta protein production
US6759404B2 (en) 2000-04-03 2004-07-06 Richard E. Olson Cyclic malonamides as inhibitors of aβ protein production
WO2004071381A2 (fr) * 2003-02-13 2004-08-26 Grünenthal GmbH Medicaments contenant des composes acide 2-arylaminoacetique substitue et/ou des composes acide 2-heteroarylaminoacetique substitue
US6794381B1 (en) 1998-08-07 2004-09-21 Bristol-Myers Squibb Company Succinoylamino lactams as inhibitors of aβ protein
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
US6900199B2 (en) 2000-04-11 2005-05-31 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of Aβ protein production
WO2005085185A1 (fr) * 2004-03-03 2005-09-15 Smithkline Beecham Corporation Derives d'aniline utilises comme modulateurs du recepteur selectif de l'androgene
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US7053084B1 (en) 1998-12-24 2006-05-30 Bristol-Myers Squibb Company Succinoylamino benzodiazepines as inhibitors of Aβ protein production
US7153491B2 (en) 1998-11-12 2006-12-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
US7300951B2 (en) 2003-03-31 2007-11-27 Wyeth Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
DE10259834B4 (de) * 2001-12-20 2007-11-29 F. Hoffmann-La Roche Ag Test und Screeningverfahren zur Identifizierung von Inhibitoren von Beta-Sekretasen
US7304055B2 (en) 1998-08-07 2007-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino lactams as inhibitors of Aβ protein production
EP1871379A2 (fr) * 2005-04-15 2008-01-02 Smithkline Beecham Corporation Cyanoarylamines
US7399778B2 (en) 2004-01-16 2008-07-15 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
EP2511267A1 (fr) 2003-06-05 2012-10-17 Elan Pharmaceuticals Inc. 3-((aminoacyl n-acylé)amino)pyrazoles comme inhibiteurs de la production de peptide beta-amyloide utiles pour le traitement de la maladie d'alzheimer
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
US8691185B2 (en) 2003-08-22 2014-04-08 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
US8911707B2 (en) 2000-08-24 2014-12-16 University of Pittsburgh—of the Commonwealth System of Higher Education Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US9833458B2 (en) 2000-08-24 2017-12-05 University of Pittsburgh—of the Commonwealth System of Higher Education Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CN111777571A (zh) * 2020-06-28 2020-10-16 武汉药明康德新药开发有限公司 一种手性2-氨基-3 -(1,3-苯并噻唑-2-基)丙酸盐酸盐的合成方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784392A (zh) * 2003-03-14 2006-06-07 匹兹堡大学 苯并噻唑衍生物化合物、组合物及用途
CN100999546B (zh) * 2007-01-11 2010-08-11 清华大学 具有含氮杂环修饰的多肽类化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009838A1 (fr) * 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITEURS DE LA PRODUCTION DE PROTEINES DE β-AMYLOIDE
WO1996020725A2 (fr) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide, analogue peptidique et analogue d'acide amine agissant comme inhibiteurs de protease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009838A1 (fr) * 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITEURS DE LA PRODUCTION DE PROTEINES DE β-AMYLOIDE
WO1996020725A2 (fr) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide, analogue peptidique et analogue d'acide amine agissant comme inhibiteurs de protease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tetrahedron, Volume 24, 1968, Y. Iwakura et al, "Reaction Of Alkylidenepseudoxazolones With Amines", page 575 - page 583, XP002900183 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304055B2 (en) 1998-08-07 2007-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino lactams as inhibitors of Aβ protein production
US7101870B2 (en) 1998-08-07 2006-09-05 Bristol-Myers Squibb Pharma Company Succinoylamino lactams as inhibitors of A-β protein production
US6962913B2 (en) 1998-08-07 2005-11-08 Bristol-Myers Squibb Company Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production
US6794381B1 (en) 1998-08-07 2004-09-21 Bristol-Myers Squibb Company Succinoylamino lactams as inhibitors of aβ protein
US7507815B2 (en) 1998-08-07 2009-03-24 Bristol-Myers Squibb Pharma Company Succinoylamino lactams as inhibitors of a-β protein production
US7304056B2 (en) 1998-08-07 2007-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino lactams as inhibitors of Aβ protein production
US6486350B1 (en) 1998-09-30 2002-11-26 Elan Pharmaceuticals Inc. Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide
US7153491B2 (en) 1998-11-12 2006-12-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
US7304049B2 (en) 1998-12-24 2007-12-04 Bristol-Myers Squibb Pharma Company Succinoylaminobenzodiazepines as inhibitors of Aβ protein production
US7718795B2 (en) 1998-12-24 2010-05-18 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of aβ protein production
US7456172B2 (en) 1998-12-24 2008-11-25 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Aβ protein production
US7053084B1 (en) 1998-12-24 2006-05-30 Bristol-Myers Squibb Company Succinoylamino benzodiazepines as inhibitors of Aβ protein production
US7342008B2 (en) 1999-09-13 2008-03-11 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US7112583B2 (en) 1999-09-13 2006-09-26 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US7423033B2 (en) 1999-09-13 2008-09-09 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503901B1 (en) 1999-10-08 2003-01-07 Bristol Myers Squibb Pharma Company Amino lactam sulfonamides as inhibitors of Aβ protein production
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
US7528249B2 (en) 2000-04-03 2009-05-05 Bristol-Myers Squibb Pharma Company Cyclic malonamides as inhibitors of aβ protein production
US7053081B2 (en) 2000-04-03 2006-05-30 Bristol-Myers Squibb Pharma Company Cyclic malonamides as inhibitors of A-β protein production
US7390896B2 (en) 2000-04-03 2008-06-24 Bristol-Myers Squibb Pharma Corporation Cyclic malonamides as inhibitors of Aβ protein production
US7276496B2 (en) 2000-04-03 2007-10-02 Bristol-Myers Squibb Pharma Company Cyclic malonamides as inhibitors of Aβ protein protection
US6759404B2 (en) 2000-04-03 2004-07-06 Richard E. Olson Cyclic malonamides as inhibitors of aβ protein production
US6713476B2 (en) 2000-04-03 2004-03-30 Dupont Pharmaceuticals Company Substituted cycloalkyls as inhibitors of a beta protein production
US6900199B2 (en) 2000-04-11 2005-05-31 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of Aβ protein production
US7498324B2 (en) 2000-04-11 2009-03-03 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of Aβ protein production
US7276495B2 (en) 2000-04-11 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of Aβ protein production
US7390802B2 (en) 2000-04-11 2008-06-24 Bristol-Myers Squibb Pharma Corporation Substituted lactams as inhibitors of Aβ protein production
US7655647B2 (en) 2000-04-11 2010-02-02 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of Aβ protein production
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
US6958329B2 (en) 2000-06-01 2005-10-25 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of A-β protein production
US7456278B2 (en) 2000-06-01 2008-11-25 Bristol-Myers Squibb Pharma Corporation Lactams substituted by cyclic succinates as inhibitors of Aβ protein production
US7354914B2 (en) 2000-06-01 2008-04-08 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of Aβ protein production
US6509333B2 (en) 2000-06-01 2003-01-21 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of Aβ protein production
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
US8911707B2 (en) 2000-08-24 2014-12-16 University of Pittsburgh—of the Commonwealth System of Higher Education Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US10137210B2 (en) 2000-08-24 2018-11-27 The University of Pittsburgh—Of the Commonwealth System of Higher Education Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US9833458B2 (en) 2000-08-24 2017-12-05 University of Pittsburgh—of the Commonwealth System of Higher Education Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US9808541B2 (en) 2000-08-24 2017-11-07 University of Pittsburgh—Of the Commonwealth System of Higher Eduation Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6610734B2 (en) 2000-12-13 2003-08-26 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
US7691884B2 (en) 2000-12-13 2010-04-06 Wyeth Heterocyclic sulfonamide inhibitors of β amyloid production
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
US7842718B2 (en) 2000-12-13 2010-11-30 Wyeth Llc Heterocyclic sulfonamide inhibitors of beta amyloid production
US6878742B2 (en) 2000-12-13 2005-04-12 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
DE10259834B4 (de) * 2001-12-20 2007-11-29 F. Hoffmann-La Roche Ag Test und Screeningverfahren zur Identifizierung von Inhibitoren von Beta-Sekretasen
WO2004071381A3 (fr) * 2003-02-13 2004-11-18 Gruenenthal Gmbh Medicaments contenant des composes acide 2-arylaminoacetique substitue et/ou des composes acide 2-heteroarylaminoacetique substitue
WO2004071381A2 (fr) * 2003-02-13 2004-08-26 Grünenthal GmbH Medicaments contenant des composes acide 2-arylaminoacetique substitue et/ou des composes acide 2-heteroarylaminoacetique substitue
US7432296B2 (en) 2003-02-13 2008-10-07 Gruenenthal Gmbh Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds
US7300951B2 (en) 2003-03-31 2007-11-27 Wyeth Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US7547725B2 (en) 2003-03-31 2009-06-16 Wyeth Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US7858658B2 (en) 2003-03-31 2010-12-28 Wyeth Llc Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
EP2511267A1 (fr) 2003-06-05 2012-10-17 Elan Pharmaceuticals Inc. 3-((aminoacyl n-acylé)amino)pyrazoles comme inhibiteurs de la production de peptide beta-amyloide utiles pour le traitement de la maladie d'alzheimer
US9134328B2 (en) 2003-08-22 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of using benzothiazole derivative compounds and compositions
US8691185B2 (en) 2003-08-22 2014-04-08 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
US7674813B2 (en) 2004-01-16 2010-03-09 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
US7399778B2 (en) 2004-01-16 2008-07-15 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
US7723385B2 (en) 2004-03-03 2010-05-25 Glaxosmithkline Llc Aniline derivatives as selective androgen receptor modulators
US7514470B2 (en) 2004-03-03 2009-04-07 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
WO2005085185A1 (fr) * 2004-03-03 2005-09-15 Smithkline Beecham Corporation Derives d'aniline utilises comme modulateurs du recepteur selectif de l'androgene
EP1871379A4 (fr) * 2005-04-15 2010-06-02 Glaxosmithkline Llc Cyanoarylamines
EP1871379A2 (fr) * 2005-04-15 2008-01-02 Smithkline Beecham Corporation Cyanoarylamines
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
CN111777571A (zh) * 2020-06-28 2020-10-16 武汉药明康德新药开发有限公司 一种手性2-氨基-3 -(1,3-苯并噻唑-2-基)丙酸盐酸盐的合成方法

Also Published As

Publication number Publication date
NZ335157A (en) 2001-01-26
HUP0001383A1 (hu) 2001-05-28
NO992426L (no) 1999-06-30
IL129477A0 (en) 2000-02-29
WO1998022493A3 (fr) 1998-07-23
CA2270876A1 (fr) 1998-05-28
EP0942923A2 (fr) 1999-09-22
AU5354398A (en) 1998-06-10
CN1237978A (zh) 1999-12-08
BR9714358A (pt) 2000-03-21
HUP0001383A3 (en) 2001-11-28
ID22275A (id) 1999-09-23
JP2001519769A (ja) 2001-10-23
TR199901132T2 (xx) 1999-08-23
NO992426D0 (no) 1999-05-20

Similar Documents

Publication Publication Date Title
WO1998022493A2 (fr) DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D&#39;INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L&#39;AIDE DE CES COMPOSES
EP0946499B1 (fr) Amides d&#39;acides amines n-(aryl/heteroaryl/alkylacetyl), compositions pharmaceutiques les contenant et methodes d&#39;inhibition de la liberation du peptide beta-amyloide et/ou sa synthese a l&#39;aide de ces composes
US6888022B2 (en) Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
EP0951464B1 (fr) Esters de n-(aryl/heteroarylacetyl) aminoacide, compositions pharmaceutiques les contenant et methodes pour inhiber la liberation du peptide de la proteine beta-amyloide et/ou sa synthese au moyen desdits composes
US6495693B2 (en) N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP0942924A2 (fr) METHODES ET COMPOSES DESTINES A INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE $g(b)-AMYLOIDE
WO1998022494A9 (fr) METHODES ET COMPOSES DESTINES A INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE
JP2008502720A (ja) 細菌の排出ポンプ阻害薬および細菌感染症を治療する方法
WO1998022441A2 (fr) ESTERS DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES ET METHODES POUR INHIBER LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU SA SYNTHESE
US6432944B1 (en) Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
US6262302B1 (en) N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US7205336B2 (en) β-secretase inhibitors
US6399628B1 (en) N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds
US6333351B1 (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
CA2388750A1 (fr) Composes contenant des .beta.-acides amines utiles pour inhiber la liberation et/ou la synthese du peptide .beta.-amyloide
MXPA99004527A (en) N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING&amp;bgr;-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
CZ9901423A3 (cs) Deriváty N-(AR¥L/HETEROARYL) aminokyselin, farmaceutické kompozice s jejich obsahem a způsoby inhibice uvolňování βAMYLOIDOVÉHO PEPTIDU a/nebo jejich syntézy použitím těchto sloučenin
KR20000069066A (ko) Ｎ-(아릴/헤테로아릴)아미노산 유도체, 이를 함유하는 약제학적조성물 및 이를 사용한 β-아밀로이드 펩티드 방출 및(또는)합성의 억제 방법
US6767918B2 (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
CZ9901630A3 (cs) Aminy N-(aryl/heteroaryl/alkylacetyl)aminokyselin, farmaceutické kompozice, které je obsahují a způsoby inhibice uvolňování beta- amyloidového peptidu a/nebo jeho syntézy použitím takových sloučenin
MXPA99004394A (en) N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING&amp;bgr;-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199776.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 335157

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 53543/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV1999-1423

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2270876

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1998 523649

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004527

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019997004489

Country of ref document: KR

Ref document number: 1999/01132

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1997950576

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997950576

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997004489

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1999-1423

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019997004489

Country of ref document: KR